 |
      
|
|
|
|
|
|||||
|
|
January 27, 2003
Neurochem to present at the annual U.S. Bancorp Piper Jaffray Healthcare Conference. About Neurochem
Neurochem is a product-driven, specialty pharmaceutical company which offers a new class
of drug candidates to prevent and stop the progression of diseases for which no cure
exists. The Company's strong and growing pipeline will meet unmet medical needs and is
focused on disorders of the central nervous system and amyloid-related diseases. Neurochem's
most advanced product candidate is Fibrillex™, in pivotal Phase II/III clinical
development for the treatment of Secondary Amyloidosis, a fatal kidney disease. Two other
product candidates in Phase II clinical development are Alzhemed™ for the treatment
of Alzheimer's disease and Cerebril™ for Hemorrhagic Stroke due to Cerebral Amyloid
Angiopathy. At the pre-clinical development stage, the Company has two potential products
targeting Diabetes Type 2 and Epileptic Seizures induced by traumatic brain
injury (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
